<DOC>
	<DOCNO>NCT01490528</DOCNO>
	<brief_summary>There little data publish long term durability infliximab pediatric patient . In particular focus durable remission , frequency dose/frequency change switch within class . Moreover 10 year safety experience rarely report child . The overall objective evaluate persistence infliximab well dose strategy pediatric inflammatory bowel disease ( IBD ) patient safety infliximab Regarding persistence infliximab investigator focus proportion patient continue durable response remission infliximab . The investigator assess measure frequency dose escalation , proportion patient needing frequency change proportion patient switch adalimumab certolizumab . Safety outcomes focus frequency malignancy , infection immunogenecity</brief_summary>
	<brief_title>Durability Tolerability Infliximab Pediatric Inflammatory Bowel Disease Patients : A 10 Year Single Center Experience</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>All individual receive least 2 dos infliximab age 16 pediatric IBD Center Cedars Sinai Medical Center treatment Crohn 's disease ulcerative colitis Able give consent expose infliximab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Pediatric IBD</keyword>
</DOC>